Session Chair Profile

Ph.D., Co-founder and Chief Scientific Officer, Viviphi Ltd.

Dr. Ashbury joined Viviphi as a founding member in 2015 to develop a first-of-its-kind comprehensive clinical pathway and precision medicine planning platform. He is responsible for developing and maintaining all clinical content, including standard of care and genomic-science knowledge identification and codification, and designing and implementing treatment strategy rules that underpin the ViviphiTM platform. Dr. Ashbury has mentored oncology practices and networks worldwide to define quality metrics based on current evidence to establish practice accountability, reporting and quality improvement.He is a member of the American Society of Clinical Oncology; board member for the Multi-National Association of Supportive Care in Cancer (MASCC); Chair of the Guidelines Committee, MASCC; member of the University of Swinburne Industry Research Advisory Committee; and Editor-in-Chief of Supportive Care in Cancer.He graduated with honors from the University of Toronto (bachelor’s), Queen’s University (master’s), and York University (doctorate).

Session Abstract

Session Synopsis: Precision Medicine (PM) leaders will discuss issues and lessons learned implementing PM programs as well as opportunities for community oncology practices. Topics include: requirements for creating a precision medicine program (personnel, supports; working with sequencing labs;interpreting results;and tools needed to scale and bring genomic-guided therapies to physicians and patients). A presentation of the PrecisionPlan™ oncology workbench to facilitate patient-specific genomic-guided treatment plans at point-of-care in real-time will support the discussion.